AMRN ANDA patent litigation: Key Considerations for Investors
Nov 21, 2025
1 min read
Experienced PhD biotech patent attorney and biopharma investor, Manny Vacchiano, discusses some key points and events in the appeal of the district court obviousness ruling of the AMRN ANDA litigation, and discusses the #1 misconception of investors with respect to the asserted patents.
Comments